Paeds Vivas · genetics-dysmorphology-and-metabolism
22q11.2 deletion syndrome — branching viva
Branching viva on 22q11.2 deletion syndrome: recognising the multisystem fingerprint that earns a chromosomal microarray, staging every system at diagnosis, deferring live vaccines until the immune system is mapped, and managing the acute neonatal presentations and the adolescent psychiatric risk.
On this page & tools
Target exams
Opening question
A twenty-four-hour-old infant has a conotruncal cardiac lesion, a cleft palate, a characteristic face, a corrected calcium of 1.5 mmol per litre, and a normal standard karyotype. What is the diagnosis, which investigation confirms it, and why was the karyotype inadequate? [1] [2]
Branch 1 — the acute neonatal threats
Take the same child. What is your immediate management of the hypocalcaemia, and how does the cardiac lesion alter your resuscitation? Now the family asks about the rotavirus and BCG vaccines on the schedule — what is the principle that governs live vaccines here, and how is the schedule cleared? [9] [2]
Branch 2 — staging the immune system
The lymphocyte subsets show a moderate T-cell lymphopenia. How do you place this child on the immune spectrum, what defines complete DiGeorge syndrome, and what would change in your management if the T-cells were near-absent? [9]
Branch 3 — the lifespan and psychiatric trajectory
Fast forward to adolescence: the same child, now with a repaired heart, presents with declining school performance and new anxiety. What is the surveillance you should already have in place, what is the significance of the schizophrenia-spectrum risk, and how does it change the plan? [12]
Closing — coordination and counselling
In one sentence, what is the principle of 22q11.2 management across the lifespan, and why does the general paediatrician sit at the centre of a multidisciplinary plan that runs from the neonatal unit to adult psychiatric care? [2] [1]
References
- [1]McDonald-McGinn DM, Sullivan KE, Marino B, et al. 22q11.2 deletion syndrome. Nat Rev Dis Primers, 2015.PMID 27189754
- [2]Bassett AS, McDonald-McGinn DM, Devriendt K, et al. Practical guidelines for managing patients with 22q11.2 deletion syndrome. J Pediatr, 2011.PMID 21570089
- [9]Crowley B, Ruffner M, McDonald McGinn DM, Sullivan KE. Variable immune deficiency related to deletion size in chromosome 22q11.2 deletion syndrome. Am J Med Genet A, 2018.PMID 29341423
- [12]Cleynen I, Engchuan W, Hestand MS, et al. Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion. Mol Psychiatry, 2021.PMID 32015465